Remove 2013 Remove 2015 Remove Clinical Trials Remove Treatment
article thumbnail

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Cannabis Law Report

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Over 1,500 people from around the world attended MAPS’ Psychedelic Science 2013 conference in Oakland, CA.

article thumbnail

Best strains and terpenes for pain management

The Cannigma

Over 10% of US adults have suffered from some degree of daily pain for at least three months, so the need for improved treatment is clear. There have been a number of preclinical and clinical trials studying cannabis’ effects on pain. 12 Pinene had the ability to meditate chemical responses to inflammation in rodent trials.

Terpenes 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

ElleVet Sciences Publishes Safety Study On CBD For Animals

Cannabis Law Report

Wakshlag is well-known in the veterinary medicine community as the first doctor to conduct an efficacy study in dogs in a clinical trial at Cornell using ElleVet CBD/CBDA on dogs with multi-joint discomfort. The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement.

Safety 45
article thumbnail

Psychedelic Invest’s 100 Most Influential People in Psychedelics List

Cannabis Law Report

there has never been a better time for new treatment options. Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. In 2015, Cannabase.io Rick Doblin, Ph.D, in/rickdoblin/ [link].

article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Lancet Neurol Dec 23 2015.

article thumbnail

NO BRAINER: CBD AND THC FOR HEAD INJURIES

Green Relief

As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. Treatment modalities for TBI are limited with few satisfactory pharmaceutical options available. An estimated 4 million to 6 million Americans are on disability because of TBI.

THC 64
article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

It was also used as a topical treatment for haemorrhoids, ear infection, and wounds (Aldrich 1997 ; Touw 1981 ). The latter remains a dangerous drug and is considered higher risk for treatment than CBD (TGA 2019 ). 2015 ; Kaiser 2011 ; Mortensen et al. No negative articles appear in these medical publications until 2015.